Progressive renal toxicity due to ifosfamide.

Heney, David; Wheeldon, John; Rushworth, Parker; Chapman, Chris; Lewis, Ian; Bailey, Chris

doi:10.1136/adc.66.8.966

Cited by 42 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In most patients, ifosfamide-associated nephrotoxicity remains stable over time. A small proportion of patients will have signifi cant improvements or worsening of both tubular and glomerular function (Heney et al 1991 ). The risk of ifosfamide-associated nephrotoxicity is associated with higher cumulative doses, younger age at the time of administration, preexisting renal dysfunction, exposure to other nephrotoxic drugs, and treatment with cisplatin (Loebstein et al 1999 ).…”

Section: Cardiac Toxicitymentioning

confidence: 99%

Malignant Pediatric Bone Tumors - Treatment & Management

Cripe¹,

Yeager²

2015

Pediatric Oncology

View full text Add to dashboard Cite

Each volume of the series "Pediatric Oncology" covers the whole spectrum of the disease concerned, from research issues to clinical management, and is edited by internationally highly respected experts in a comprehensive and clearly structured way. The user-friendly layout allows quick reference to in-depth information. The series is designed for all health-care personnel interested in high-level education in pediatric oncology.More information about this series at

show abstract

Section: Cardiac Toxicitymentioning

confidence: 99%

Malignant Pediatric Bone Tumors - Treatment & Management

Cripe¹,

Yeager²

2015

Pediatric Oncology

View full text Add to dashboard Cite

show abstract

“…In many instances cancer treatment can do a lot of harm. For example, although the antineoplastic agent ifosfamide is widely used in the treatment of many childhood solid tumors, [28][29][30][31] it has a high rate of serious adverse effects. It is accepted that the drug causes bladder cystitis, [32] neurotoxicity [33] and nephrotoxicity.…”

Section: Beneficence/nonmaleficencementioning

confidence: 99%

Ethical Issues in Including Pediatric Cancer Patients in Drug Development Trials

Aleksa

Koren

2002

Pediatric Drugs

View full text Add to dashboard Cite

Since the biology, pharmacology and toxicology of pediatric cancer is so different from cancer in adults, it is impossible to extrapolate from adult cancer experience; however, conducting studies in children with cancer is ethically and clinically very complex. This is especially so in phase 1 trials, aimed at dose finding for new modalities, where the chances to cure the child who failed standard therapy are marginal to non-existent. Hence, the child may be exposed to risks and discomfort which may be unbalanced by potential benefits. This situation, which is difficult for consenting adults, is much more complex when a parent gives proxy consent. This review addresses the ethical and clinical framework of such studies in the most vulnerable of children.

show abstract

“…Briefly, transient elevation of the urinary N-acetyl-ß-D-glucosaminidase index was observed in newborns and children treated with gentamicin (81,124,125), netilmicin (126)(127)(128), tobramycin (39,81,129), amikacin (130)(131)(132)(133), vancomycin (134) and aztreonam (135). Elevated N-acetyl-ß-D-glucosaminidase indices have been measured in children receiving cis-diamminedichloroplatinum (cisplatin) (136,141), methotrexate (137-140), carboplatin (142) and ifosfamide (143)(144)(145)(146)(147). Elevated N-acetyl-ß-D-glucosaminidase indices have been measured in children receiving cis-diamminedichloroplatinum (cisplatin) (136,141), methotrexate (137-140), carboplatin (142) and ifosfamide (143)(144)(145)(146)(147).…”

Section: Nephrotoxicity Of Drugsmentioning

confidence: 99%

Review

1995

CCLM

View full text Add to dashboard Cite

More recently numerous papers have been written on the successful paediatric applications of some well-established urinary N-acetyl-ß-D-glucosaminidase assays by several authors. Regarding these developments we tried to collect and summarize all the available literature data published in this field thus far and, in addition, to encourage and promote the wider utilization of these effective methods for the diagnosis of very different primary and secondary renal damages. Besides the chemical and biochemical background of the assays the pathological conditions and medical treatments which may lead to tubulopathy and, therefore, to a significantly elevated urinary enzyme excretion are also discussed. (15, 17) because its filtration through glomeruli is normally precluded (Af r 130000) (18).

show abstract

Progressive renal toxicity due to ifosfamide.

Abstract: A prospective and follow up study of renal tubular and glomerular function in 11 children receiving ifosfamide treatment was con-

Cited by 42 publications

References 13 publications

Malignant Pediatric Bone Tumors - Treatment & Management

Malignant Pediatric Bone Tumors - Treatment & Management

Ethical Issues in Including Pediatric Cancer Patients in Drug Development Trials

Review

Contact Info

Product

Resources

About